The most recent and probably most important change in the field of oncology in recent years has been the development of immunooncology, especially immune control point inhibitors. The use of monoclonal antibodies targeting PD-1 and PD-L1 has significantly altered the approach to cancer therapy. Indeed, these drugs are effective on a wide range of cancers, have few side effects and lead to lasting responses in metastatic patients. However, in most cancers, efficacy is limited to about a quarter of patients treated. We propose to determine the most optimal combination of a chemotherapeutic agent with inhibitors targeting PD1/PD-L1 and the discovery of new immunotherapy response markers. Thanks to our clinical partners, we have access to clinically well annotated cohorts of patients with biological samples of high quality blood and tumor material available prior to treatment, during treatment and during relapse. The main objectives of this transactional research project are: 1.What patients are more likely to respond to PD-1/PD-L1 inhibitors? 2.How to combine this immunotherapy with other therapies? 3.Is immunosuppression a target of immunotherapy? 4.How to develop new targeted immunotherapy?